Arcturus Therapeutics Holdings Inc.

ARCT

NASDAQHealthcareBiotechnology

GoAI で開く

GoAIリサーチ・スナップショット

利用可能な最新のモデル情報を簡潔にまとめています。

2026年7月10日

32/ 100

GoAI スコア

Sell

Trim exposure — unfavorable risk-reward

バリュエーション

Fair Value

モメンタム

Weakening

センチメント

Mixed

リスク耐性

High Risk

GoAIの詳細リサーチ

詳しい根拠、カタリスト、リスクを確認できます。

詳細リサーチを見る

AI によって生成されたコンテキストは情報提供のみを目的としており、投資アドバイスではありません。

企業プロフィール

会社ウェブサイト

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

業界: Biotechnology
セクター: Healthcare
本社: US
最高経営責任者（CEO）: Joseph E. Payne
上場以来: 2013年5月22日
従業員: 109